Pitressin®
(vasopressin injection, USP), Synthetic

Product Summary


Therapeutic Area: Hospital Products
This product is distributed by: JHP Pharmaceuticals, LLC

Full Prescribing Information

MSDS Sheet

Pitressin MSDS

For additional product information please see our contact page.

-A sterile, aqueous solution of synthetic vasopressin (8-Arginine vasopressin) of the posterior pituitary gland

-For prevention and treatment of postoperative abdominal distention

-Adjunctive therapy to dispel (interfering) gas shadows in abdominal roentgenography

-For treatment for diabetes insipidus

DESCRIPTION

Pitressin® (vasopressin injection, USP), Synthetic is a sterile, aqueous solution of synthetic vasopressin (8-Arginine vasopressin) of the posterior pituitary gland.  It is substantially free from the oxytocic principle and is standardized to contain 20 pressor units/mL.  The solution contains 0.5% Chlorobutanol (chloroform derivative) as a preservative.  The acidity of the solution is adjusted with acetic acid.

INDICATIONS AND USAGE

Pitressin® is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus.

CONTRAINDICATIONS

Anaphylaxis or hypersensitivity to the drug or its components.

WARNINGS

This drug should not be used in patients with vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate anginal pain, and with larger doses, the possibility of myocardial infarction should be considered. Vasopressin may produce water intoxication. The early signs of drowsiness, listlessness, and headaches should be recognized to prevent terminal coma and convulsions.

ADVERSE REACTIONS

Local or systemic allergic reactions may occur in hypersensitive individuals. The following side effects have been reported following the administration of vasopressin.
Body as a Whole: anaphylaxis (cardiac arrest and/or shock) has been observed shortly after injection of vasopressin.
Cardiovascular: cardiac arrest, circumoral pallor, arrhythmias, decreased cardiac output, angina, myocardial ischemia, peripheral vasoconstriction, and gangrene.
Gastrointestinal: abdominal cramps, nausea, vomiting, passage of gas.
Nervous System: tremor, vertigo, “pounding” in head.
Respiratory: bronchial constriction.
Skin and Appendages: sweating, urticaria, cutaneous gangrene.
Overdosage:

Water intoxication may be treated with water restriction and temporary withdrawal of vasopressin until polyuria occurs. Severe water intoxication may require osmotic diuresis with mannitol, hypertonic dextrose, or urea alone or with furosemide.

 

Please see the full prescribing information link above for additional information.

Documents marked with this icon are presented in Portable Document Format (PDF) to retain the original format. To view or print this document, you must use the Adobe® Acrobat® Reader®. Acrobat® Reader® is free and available directly from Adobe’s Web site with full installation instructions. You can either view and print this document or save it to your computer’s hard drive to open later. Your method may vary depending on your operating system and browser type.
 

"Adobe" and "the Adobe logo" are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries. 
   

Return To The Products Listings Page »


 
 
Enlarge Image »

Pitressin®
(vasopressin injection, USP)
 

 


To contact JHP Pharmaceuticals regarding product information or general questions, please
contact us
»


Request additional information about JHP Pharmaceuticals.
request additional information
»
 

 
Home  |  About The Company  |  Press Releases & News  |  Products  |  Manufacturing Services  |  Careers  |  Request Information  |  Contact Us  
 

Terms Of Service  |  Privacy Policy  |  Site Map

© JHP Pharmaceuticals. All Rights Reserved. Website Design by Sixty Five Design